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 1 
Abstract 
 
The N-Boc-protected (S)-prolinamine reacts easily with formaldehyde and diverse α-
hydroxyimino ketones to give imidazole N-oxides with an enantiomerically pure N-
protected (pyrrolidin-2-yl)methyl substituent. Subsequent deprotection yields the 
corresponding NH derivatives. Upon treatment of these products with Ac2O at room 
temperature, a cascade of reactions leads to optically active tricycyclic products. In all 
these processes, the stereogenic centre is preserved. In one case, the bis-heterocyclic 
imidazole N-oxide was transformed to the corresponding optically active imidazole-2-
thione via the sulfur-transfer reaction with 2,2,4,4-tetramethylcyclobutane-1,3-
dithione. 
 
1. Introduction 
 
The pyrrolidine system is well known as an important structural unit of organic 
molecules with biological activity.2 Moreover, optically active pyrrolidine-containing 
compounds derived from proline are with fundamental importance for the preparation 
of most efficient ligands and organocatalysts.3 However, relatively little is known 
about the synthesis and applications of enantiomerically pure bis-heterocycles 
containing the pyrrolidine ring. In a series of recent publications, we reported 
syntheses of optically active imidazole derivatives, and the method used was based on 
a cyclization reaction, in which primary aliphatic amines 1 and α-hydroxyimino 
ketones 2 were the starting materials for the preparation of imidazole N-oxides 34 
(Scheme 1). 
Searching for new primary amines, which can be used in this procedure as a 
chirality platform, we recently applied N-protected ‘prolinamine’ (2-
(aminomethyl)pyrrolidine, 1a) to prepare a number of bisheterocycles of type 4, in 
which an imidazole N-oxide function was present.5 These products can easily be 
converted into other imidazole derivatives such as imidazole-2-thiones, imidazol-2-
ones, or deoxygenated analogs.4,5 Regarding the efficiency of pyrrolidine-derived 
organocatalysts, an important feature of the structure is the substitution pattern of the 
N-atom. For the reactions, which occur via iminium salts, the non-protected N-atom is 
with vital importance. In the previous paper,5 we described the synthesis and selected 
conversions of N-benzyl-substituted bis-heterocycles 4, which subsequently should be 
 2 
deprotected by treatment either with Raney-Ni or by hydrogenation over Pd/C. In both 
cases, the reaction results in the deoxygenation of the imidazole oxide. In the 
hydrogenation experiment, the deoxygenation occurred simultaneously with the 
debenzylation.5 
In order to elaborate a protocol for the selective deprotection of imidazole N-
oxides of type 4, we report now on the application of N-Boc-protected proline amine 
in the multistep synthesis leading to these compounds. 
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2. Results and discussion 
 
The starting material, N-Boc-protected (S)-proline amine (1b), was obtained 
from (S)-proline via Boc-protection, reduction of the carboxyl group, replacement of 
the hydroxy by the azido group, and reduction of the latter, based on the recently 
published procedures.6 Subsequently, amine 1b was treated with paraformaldehyde in 
methanol yielding the corresponding imine 5 [7], which was the starting material for 
the reaction with α-hydroxyimino ketones 2, leading to the N-Boc-protected bis-
heterocyclic N-oxides 6 (Scheme 2). The latter were obtained as crystalline materials, 
and their structure was confirmed by their spectroscopic data. In all cases, the bridging 
CH2 group appeared in the 1H NMR spectrum as an AB system, and the most 
 3 
characteristic signal of H-C(2) of the imidazole ring was found downfield-shifted at 
7.79-8.08 ppm. 
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Characteristically, in the 1H NMR spectra of N-oxides 6 in CDCl3 at room 
temperature, the signal of the Boc group was broadened. However, it appeared as a 
sharp signal when the spectra were registered in DMSO-d6 at 80oC. 
 
The deprotection of the pyrrolidine N-atom in compounds 6 was smoothly 
performed using trifluoroacetic acid (TFA) in CH2Cl2 solution at room temperature. In 
contrast to the attempted debenzylations,5 in all cases studied the N-oxide function in 
the imidazole ring was preserved and, therefore, the N-deprotected bis-heterocycles 7 
could be used for further transformations of the imidazole moiety. Thus, treatment of 
7d with 2,2,4,4-tetramethylcyclobutane-1,3-dithione9 in CHCl3 at 0 oC led to the 
imidazole-2-thione derivative 8 (Scheme 3). This so-called sulfur-transfer reaction is 
well established for 2-unsubsituted imidazole N-oxides4,5 and offers a straight-forward 
access to biologically active imidazole-2-thione derivatives.10 
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As reported in a previous publication, treatment of 2-unsubstitued imidazole N-
oxides with Ac2O, depending on the reaction conditions, leads to isomeric imidazol-2-
ones or their N-acetylated derivatives.11 In a series of experiments, the N-oxides 7 in 
CH2Cl2 were treated with Ac2O at room temperature, and the products 9, isolated as 
viscous oils, did not contain C=O groups (IR). In addition, the 1H NMR spectra proved 
the absence of the characteristic signal of the imidazole H-C(2). Furthermore, the 
comparison of the signal pattern in the aliphatic region displayed by compounds 7 and 
the new products 9 suggested a substantial change in the structures. The appearance of 
a signal located at 159.1 ppm in the 13C NMR spectrum of 9a suggested the presence 
of a C=N group. Finally, the ESI-MS of 9a with m/z = 302.16494 ([M+1]+) evidenced 
the molecular mass of C20H19N3, which can be attributed to a product formed from 7a 
via formal loss of H2O. Based on these data, the tricyclic structure 9a being the 
product of the heterocyclization of the starting N-oxide, is proposed (Scheme 4). The 
analogous products 9b-9d were obtained starting with the N-oxides 7b-7d, 
respectively. 
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The proposed reaction pathway leading to the unknown tricyclic products 9 is 
presented in Scheme 5. Apparently, the initial acetylation occurs at the N-oxide group, 
and the intermediate cation A undergoes the heterocyclization to give B, which 
rearomatizes via elimination of AcOH. An analogous explanation for the 
heterocyclization observed in the case of 1-(β-hydroxypropyl)-imidazol-3-oxide upon 
treatment with Ac2O was described recently.12 Another case of the activaction of C(2) 
in imidazole N-oxides towards the nucleophilic addition of water was reported for the 
reaction with electron-deficient 2,2-bis(trifluoromethyl)ethane-1,1-dicarbonitrile.13 
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3. Conclusion 
 
The results of this study show that bis-heterocycles containing the non-
protected pyrrolidine and imidazole N-oxide linked via a methylene group can be 
prepared from N-Boc-protected prolinamine in an enantiopure form. The deprotection 
of the pyrrolidine ring with TFA occurs without change of the N-oxide moiety. 
Treatment of the N-oxide derivatives containing the non-protected pyrrolidine ring 
with Ac2O leads to the hitherto unknown tricyclic N-heterocycles identified as 5H-
pyrro[1,2-c]imidazo[1,2-a]imidazole derivatives. The obtained enantiomerically pure 
products are of interest as potential ligands for asymmetric synthesis. Similar byciclic 
systems derived from proline are reported as prone catalysts for, e.g., 
desymmetrization of meso-1,2-diols.14 
 
4. Experimental 
 
4.1. General 
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Melting points were determined in a capillary using a Melt-Temp. II apparatus 
(Aldrich) or STUART SMP30 and are uncorrected. The IR Spectra were recorded on a 
NEXUS FT-IR spectrophotometer in KBr; absorptions in cm-1. The 1H and 13C{1H} 
NMR spectra were measured on a Bruker Avance III instrument (600 and 150 MHz, 
resp.) using solvent signal as reference. Multiplicity of signals in the 13C NMR spectra 
was established using the HMQC technique. Chemical shifts (δ) are given in ppm and 
coupling constants J in Hz. Assignments of signals in 13C NMR spectra were made on 
the basis of HMQC experiments. HR-MS: Bruker maxis spectrometer; ESI-MS: 
Varian 500 instrument. Optical rotations were determined on a PERKIN-ELMER 241 
MC polarimeter for λ = 589 nm. 
 
4.2 General procedure for the synthesis of compounds 6. 
 
To the solution of Boc-prolinamine (200.0 mg, 1.0 mmol) in MeOH (3 mL) 
paraformaldehyde (30.0 mg, 1.10 mmol) was added at room temperature and the 
mixture was stirred over night. Then, the solvent was evaporated and the obtained 
imine was dissolved in EtOH (4 mL). To this solution, an equimolar amount of the 
corresponding α-hydroxyimino ketone was added and the mixture was heated at reflux 
for 3 h. Next, the solvent was removed under reduced pressure and the resulting 
residue was purified by column chromatography or by crystallization. 
 
4.2.1. 1-{[(2S)-N-Boc-pyrrolidin-2-yl]methyl}-4,5-diphenyl-1H-imidazole 
3-oxide (6a). Yield: 0.348 g (83%). Colorless crystals. Mp. 218–220°C (Et2O). IR 
(KBr): ν 3420br, 2974m, 1682s, 1393m, 1363m, 1183m, 1122m, 1090m, 978m, 
753m. 1H NMR (CDCl3): δ 8.08 (s, 1H, HC(2)); 7.55–7.51 (m, 2H, HC(arom.)); 7.45–
7.41 (m, 3H, HC(arom.)); 4.08–4.72 (m, 1H, HC(2’), 2H, H2C); 3.36–2.98 (m, 1H, 
HC(5’)); 1.88–1.64 (m, 1H, H2C(3’), 1H, H2C(4’)); 1.45 (s, 9H, t-Bu); 1.43–1.32 (m, 
1H, H2C(3’), 1H, H2C(4’)). 13C NMR (CDCl3): δ 155.0 (C=O); 131.1 (CH(arom.)); 
130.6 (C(arom.)); 129.8, (CH(arom.)); 129.7 (C(arom.)); 129.4 (CH(arom.)); 128.3 
(C(imid.)); 128.2 (CH(arom.)); 127.7, 127.6, 127.0 (C(arom.)); 126.4 (C(2)); 80.6 
(Me3C); 57.4 (C(2’)); 47.6 (CH2); 47.1 (C(5’)); 28.7 (Me3C); 22.7 (C(3’)); 22.7 
(C(4’)). HR-ESI-MS (MeOH + HCOOH): 420.22828 (calcd 420.22817 for 
C25H30N3O3, [M+1]+). [α]D25 = –8 (c 0.625, CH2Cl2). 
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 4.2.2. 1-{[(2S)-N-Boc-pyrrolidin-2-yl]methyl}-4,5-dimethyl-1H-imidazole 
3-oxide (6b). Yield: 0.259 g (88%). Pale yellow oil (SiO2, AcOEt/MeOH, 7:3 
(+Et3N)). IR (ﬁlm): ν 3397–2931br, 1689m, 1456m, 1405m, 1341m, 1170m, 1107m, 
976m, 773m. 1H NMR (CDCl3): δ 7.94 (s, 1H, HC(2)); 4.10–3.70 (m, 1H, HC(2’), 2H, 
H2C); 3.35–3.08 (m, 2H, H2C(5’)); 2.16 (s, 3H, Me); 2.13 (s, 3H, Me); 1.93–1.61 (m, 
2H, H2C(3’), 2H, H2C(4’)); 1.42 (s, 9H, t-Bu). 13C NMR (CDCl3): δ 155.0 (C=O); 
126.8 (C(imid.)); 125.3 (C(2)); 121.9 (C(imid.)); 80.3 (Me3C); 57.0 (C(2’)); 47.6 
(CH2); 47.1 (C(5’)); 28.6 (Me3C); 27.9 (C(3’)); 23.7 (C(4’)); 8.9 (Me); 7.4 (Me). HR-
ESI-MS (MeOH + NaI): 296.19695 (calcd 296.19687 for C15H26N3O3, [M+1]+). [α]D25 
= –24 (c 0.5, CH2Cl2). 
 
4.2.3. 1-{[(2S)-N-Boc-pyrrolidin-2-yl]methyl}-4-methyl-5-phenyl-1H-
imidazole 3-oxide (6c). Yield: 0.275 g (77%). Pale yellow oil (SiO2, AcOEt/MeOH, 
1:1 (+Et3N)). IR (ﬁlm): ν 3390–2976br, 1683m, 1456m, 1397m, 1366m, 1167m, 
1105m, 975m, 766m. 1H NMR (CDCl3): δ 7.91 (s, 1H, HC(2)); 7.53–7.45 (m, 3H, 
HC(arom.)); 7.32–7.26 (m, 2H, HC(arom.)); 4.10–3.70 (m, 2H, H2C, 1H, HC(2’)); 
3.32–2.94 (m, 2H, H2C(5’)); 2.21 (s, 3H, Me); 1.83–1.60 (m, 1H, H2C(3’), 1H, 
H2C(4’)); 1.42 (s, 9H, t-Bu); 1.37–1.23 (m, 1H, H2C(3’), 1H, H2C(4’)). 13C NMR 
(CDCl3): δ 155.0 (C=O); 130.6 (CH(arom.)); 129.6 (C(imid.)); 129.4 (CH(arom.)); 
128.3 (C(imid.)); 127.7 (C(arom.)); 127.1 (CH(arom.)); 125.5 (C(2)); 81.2 (Me3C); 
57.3 (C(2’)); 47.3 (CH2); 47.1 (C(5’)); 28.6 (3 CH3); 23.6 (C(3’)); 22.6 (C(4’)); 7.9 
(Me). HR-ESI-MS (MeOH + NaI): 358.21273 (calcd 358.21252 for C20H28N3O3, 
[M+1]+). [α]D25 = +99 (c 0.25, CH2Cl2). 
 
4.2.4. N-Phenyl-1-{[(2S)-N-Boc-pyrrolidin-2-yl]methyl}-5-methyl-1H-
imidazole-4-carboxamide 3-oxide (6d). Yield: 0.288 g (72%). Colorless crystals. 
Mp. 208–210°C (Et2O). IR (KBr): ν 3439br, 2983m, 1698m, 1598m, 1390m, 1311m, 
1167m, 1122m, 759m. 1H NMR (CDCl3): δ 12.91 (s, 1H, NH); 7.79 (s, 1H, HC(2)); 
7.72–7.68 (m, 2H, HC(arom.)); 7.35–7.30 (m, 2H, HC(arom.)); 7.12–7.07 (1H, 
HC(arom.)); 4.17–3.98 (m, 1H, HC(2’), 2H, H2C); 3.42–3.23 (m, 2H, H2C(5’)); 2.70 
(s, 3H, Me); 2.06–1.96 (m, 1H, H2C(3’)); 1.89–1.80 (m, 1H, H2C(4’)); 1.77–1.71 (m, 
1H, H2C(3’)); 1.68–1.59 (m, 1H, H2C(4’)); 1.47 (s, 9H, t-Bu). 13C NMR (CDCl3): δ 
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157.6 (C=O); 155.3 (C=O); 138.1 (C(arom.)); 131.9 (C(imid.)); 128.9 (2 CH(arom.)); 
125.3 (C(2)); 124.0 (CH(arom.)); 122.1 (C(imid.)); 120.6 (2 CH(arom.)); 81.0 (Me3C); 
57.0 (C(2’)); 47.5 (CH2); 47.2 (C(5’)); 28.6 (Me3C); 28.6 (C(3’)); 28.5 (C(4’)); 10.2 
(Me). HR-ESI-MS (MeOH + HCOOH): 401.21853 (calcd 401.21833 for C21H29N4O4, 
[M+1]+). [α]D25  = –12 (c 0.55, CH2Cl2). 
 
4.3. General procedure for the synthesis of compounds 7. 
 
To the solution of the corresponding imidazole N-oxide 6 (1 mmol) in CH2Cl2 
(5 mL) trifluoroacetic acid (13 mL) in CH2Cl2 (13 mL) was added. After all of 6 was 
consumed (monitored by TLC) the solvent was evaporated and the residue was 
dissolved in CH2Cl2 (4 mL). Then, NaHCO3 was added and the mixture was 
magnetically stirred for 3 h. Next, the solid was filtered and the filtrate was 
concentrated by evaporation in a rotary evaporator. The crude product 7 was purified 
by column chromatography. 
 
4.3.1. {[(2S)-Pyrrolidin-2-yl]methyl}-4,5-diphenyl-1H-imidazole 3-oxide 
(7a). Yield: 0.220 g (69%). Pale yellow oil (SiO2, AcOEt/MeOH, 1:1 (+Et3N)). IR 
(ﬁlm): ν 3432br, 2979w, 2780m, 2471m, 1675s, 1447m, 1430m, 1205m, 1173w, 
1130m, 833m, 798m, 762m, 721m, 704m. 1H NMR (CDCl3): δ 9.24 (s, 1H, HC(2)); 
7.50–7.41 (m, 5H, HC(arom.)); 7.37–7.33 (m, 2H, HC(arom.)); 7.31–7.25 (m, 3H, 
HC(arom.)); 4.58 (dd, 2JH,H = 15.0, 3JH,H = 10.2, 1H, H2C–N); 4.15 (dd, 2JH,H = 15.0, 
3JH,H = 3.0, 1H, H2C–N); 3.74–3.66 (m, 1H, HC(2’)); 3.11–3.03 (m, 1H, H2C(5’)); 
2.98–2.91 (m, 1H, H2C(5’)); 1.95–1.73 (m, 1H, H2C(3’), 2H H2C(4’)); 1.64–1.55 (m, 
1H, H2C(3’)). 13C NMR (CDCl3): δ 131.2, 130.7, 130.4, 130.3, 129.6, 129.1, 129.0, 
128.4, 128.0, 126.3, 125.8 (2 C(arom.), 6 CH(arom.), 2 C(imid.), C(2)); 59.3 (C(2’)); 
47.2 (CH2); 45.1 (C(5’)); 28.4 (C(3’)); 23.3 (C(4’)). HR-ESI-MS (MeOH + NaI): 
320.17559 (calcd 320.17574 for C20H22N3O, [M+1]+). [α]D25  = +81 (c 0.5, CH2Cl2). 
 
4.3.2. {[(2S)-Pyrrolidin-2-yl]methyl}-4,5-dimethyl-1H-imidazole 3-oxide 
(7b). Yield: 0.185 g (95%). Pale yellow oil (SiO2, AcOEt/MeOH, 1:1 (+Et3N)). IR 
(ﬁlm): ν 3304br, 2960m, 1688m, 1629m, 1448m, 1382m, 1200m, 1147m, 927m, 
731m. 1H NMR (CDCl3): δ 8.06 (s, 1H, HC(2)); 3.78 (dd, 2JH,H = 14.4, 3JH,H = 4.8, 1H, 
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H2C–N); 3.72 (dd, 2JH,H = 14.4, 3JH,H = 8.4, 1H, H2C–N); 3.39–3.33 (m, 1H, HC(2’)); 
2.94–2.86 (m, 2H, H2C(5’)); 2.09 (s, 3H, Me); 2.07 (s, 3H, Me); 1.91–1.84 (m, 1H, 
H2C(3’)); 1.81–1.73 (m, 1H, H2C(4’)); 1.72–1.64 (m, 1H, H2C(4’)); 1.41–1.33 (m, 1H, 
H2C(3’)). 13C NMR (CDCl3): δ 126.0 (C(2)); 125.1 (C(imid.)); 121.1 (C(imid.)); 58.0 
(C(2’)); 50.1 (CH2); 46.2 (C(5’)); 29.0 (C(3’)); 25.1 (C(4’)); 8.8 (Me); 7.2 (Me). HR-
ESI-MS (MeOH + NaI): 196.14431 (calcd 196.14444 for C10H18N3O, [M+1]+). [α]D25  
= +53 (c 0.25, CH2Cl2). 
 
4.3.3. {[(2S)-Pyrrolidin-2-yl]methyl}-4-methyl-5-phenyl-1H-imidazole 3-
oxide (7c). Yield: 0.164 g (64%). Pale yellow oil (SiO2, AcOEt/MeOH, 1:1 (+Et3N)). 
IR (ﬁlm): ν 3435br, 3057w, 2776w, 2505w, 1683s, 1446m, 1428m, 1267m, 1201m, 
1135m, 1014w, 835m, 798m, 721m, 703m. 1H NMR (CDCl3): δ 9.23 (s, 1H, HC(2)); 
7.57–7.53 (m, 3H, HC(arom.)); 7.41–7.37 (m, 2H, HC(arom.)); 4.72 (dd, 2JH,H = 15.0, 
3JH,H = 10.2, 1H, H2C–N); 4.30 (dd, 2JH,H = 15.0, 3JH,H = 3.0, 1H, H2C–N); 3.60–3.53 
(m, 1H, HC(2’)); 3.56–3.40 (m, 1H, H2C(5’)); 3.28–3.21 (m, 1H, H2C(5’)); 2.18 (s, 
3H, Me)); 2.12–2.03 (m, 1H, H2C(3’)); 1.97–1.83 (m, 2H, H2C(4’)); 1.72–1.64 (m, 
1H, H2C(3’)). 13C NMR (CDCl3): δ 130.9 (CH(arom.)); 130.7 (CH(arom.)); 130.0 
(C(arom.)); 129.9 (CH(arom.)); 128.6 (C(imid.)); 127.6 (C(2)); 125.4 (C(imid.)); 59.6 
(C(2’)); 47.1 (CH2); 45.2 (C(5’)); 28.0 (C(3’)); 23.2 (C(4’)); 7.4 (Me). HR-ESI-MS 
(MeOH + HCOOH): 258.16039 (calcd 258.16009 for C15H20N3O, [M+1]+). [α]D25  = 
+58 (c 0.25, CH2Cl2). 
 
4.3.4. N-Phenyl-{[(2S)-pyrrolidin-2-yl]methyl}-5-methyl-1H-imidazole-4-
carboxamide 3-oxide (7d). Yield: 0.153 g (51%). Pale yellow oil (SiO2, 
AcOEt/MeOH, 1:1 (+Et3N)). IR (ﬁlm): ν 3423br, 3140w, 2952m, 2872m, 1659s, 
1617m, 1596m, 1563m, 1449m, 1417m, 1309s, 1277s, 1132m, 1105m, 908m, 763s, 
695m, 624m. 1H NMR (CDCl3): δ 12.98 (s, 1H, HN); 8.05 (s, 1H, HC(2)); 7.73–7.68 
(m, 2H, HC(arom.)); 7.35–7.30 (m, 2H, HC(arom.)); 7.12–7.07 (m, 1H, HC(arom.)); 
3.88 (dd, 2JH,H = 14.4, 3JH,H = 4.2, 1H, H2C–N); 3.39 (dd, 2JH,H = 14.4, 3JH,H = 8.4, 1H, 
H2C–N); 3.47–3.40 (m, 1H, HC(2’)); 3.00–2.95 (m, 1H, H2C(5’)); 2.92–2.87 (m, 1H, 
H2C(5’)); 2.68 (s, 3H, Me); 2.00–1.93 (m, 1H, H2C(3’)); 1.85–1.78 (m, 1H, H2C(4’)); 
1.77–1.69 (m, 1H, H2C(4’)); 1.43–1.36 (m, 1H, H2C(3’)). 13C NMR (CDCl3): δ 157.8 
(C=O); 138.2, 131.2 (2 C(arom.)); 128.9 (CH(arom.)); 125.8 (C(2)); 124.0 
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(CH(arom.)); 121.7 (C(arom.)); 120.6 (CH(arom.)); 57.5 (C(2’)); 50.6 (CH2); 46.6 
(C(5’)); 29.2 (C(3’)); 25.8 (C(4’)); 9.9 (Me). HR-ESI-MS (MeOH + NaI): 301.16578 
(calcd 301.16590 for C16H21N4O2, [M+1]+). [α]D25  = +28 (c 1.0, CH2Cl2). 
 
4.4. N-Phenyl-{[(2S)-pyrrolidin-2-yl]methyl}-5-methyl-2-thioxo-2,3-
dihydro-1H-imidazole-4-carboxamide (8). To the solution of imidazole N-oxide 7d 
(1 mmol) in CHCl3 (4 mL) 2,2,4,4-tetramethylcyclobutanone-1,3-dithione (2 mmol) in 
CHCl3 (2 mL) was added at 0ºC and the mixture was stirred over night. Then, the 
solvent was removed and the residue was washed with hexane. Yield of 8: 0.193 g 
(61%). Colorless crystals. Mp. 234°C (decomp., hexane). IR (KBr): v 3432br, 3325m, 
2920m, 1683m, 1659m, 1592m, 1513m, 1432m, 1205m, 1185m, 1136m, 1066m, 
804m, 725m. 1H NMR (DMSO-d6): δ 9.55 (s, 1H, HN); 7.69–7.65 (m, 2H, 
HC(arom.)); 7.36–7.32 (m, 2H, HC(arom.)); 7.11–7.06 (m, 1H, HC(arom.)); 4.06 (dd, 
2JH,H = 14.2, 3JH,H = 4.4, 1H, H2C–N); 3.90 (dd, 2JH,H = 14.2, 3JH,H = 8.8, 1H, H2C–N); 
3.69–3.64 (m, 1H, HC(2’)); 2.92–2.85 (m, 2H, H2C(5’)); 2.53 (s, 3H, Me); 1.89–1.76 
(m, 1H, H2C(4’), 1H, H2C(3’)); 1.69–1.61 (m, 1H, H2C(4’)); 1.55–1.48 (m, 1H, 
H2C(3’)). 13C NMR (DMSO-d6): δ 160.6 (C=S); 158.5 (C=O); 139.2 (C(arom.)); 
134.1 (C(imid.)); 129.2 (2 CH(arom.)); 129.0 (C(imid.)); 123.9 (CH(arom.)); 120.0 (2 
CH(arom.)); 58.3 (C(2’)); 47.6 (CH2); 45.9 (C(5’)); 29.1 (C(3’)); 25.6 (C(4’)); 10.8 
(Me). HR-ESI-MS (MeOH + NaI): 317.14331 (calcd 317.14306 for C16H21N4OS, 
[M+1]+). [α]D25 = +16 (c 1.0, DMSO). 
 
4.5. General procedure for the synthesis of compounds 9.  
 
To a solution of the corresponding imidazole N-oxide 7 (1 mmol) in CH2Cl2 (5 
mL), freshly distilled acetic anhydride (10 mL) was added at room temperature. After 
all of 7 was consumed (monitored by TLC), MeOH (5 mL) was added to the solution 
and stirring was continued for 10 min. Next, the solvent was evaporated and the crude 
product was purified by column chromatography (AcOEt/hexane 3:7). 
 
4.5.1. (5aS)-2,3-Diphenyl-5a,6,7,8-tetrahydro-5H-pyrrolo[1,2-
c]imidazo[1,2-a]imidazole (9a). Yield: 0.216 g (72%). Colorless oil (SiO2, 
AcOEt/MeOH, 7:3). IR (ﬁlm): ν 3412br, 2927m, 1671m, 1602m, 1447m, 1335m, 
1212m, 1071m, 771m, 699m. 1H NMR (CDCl3): δ 7.54–7.51 (m, 2H, HC(arom.)); 
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7.34–7.31 (m, 2H, HC(arom.)); 7.28–7.15 (m, 4H, HC(arom.)); 7.17–7.11 (m, 2H, 
HC(arom.)); 4.42–4.36 (m, 1H, HC(2’)); 4.17–4.11 (m, 1H, H2C); 3.88–3.83 (m, 1H, 
H2C); 3.65–3.59 (m, 1H, H2C(5’)); 3.42–3.37 (m, 1H, H2C(5’)); 2.16–2.10 (m, 1H, 
H2C(3’)); 2.03–1.90 (m, 2H, H2C(4’)); 1.69–1.61 (m, 1H, H2C(3’)). 13C NMR 
(CDCl3): δ 159.1 (C=N); 139.1 (1 C(arom.)); 135.2, 131.1 (2 C(imid.)); 128.8, 128.2, 
128.1, 127.2, 126.4 (10 CH(arom.)); 121.8 (1 C(arom.)); 67.7 (C(2’)); 50.8 (C(5’)); 
48.3 (CH2); 31.8 (C(3’)); 26.1 (C(4’)). HR-ESI-MS (MeOH + HCOOH): 302.16494 
(calcd 302.16517 for C20H20N3, [M+1]+). [α]D25  = –35 (c 0.25, CH2Cl2). 
 
4.5.2. (5aS)-2,3-Dimethyl-5a,6,7,8-tetrahydro-5H-pyrrolo[1,2-
a]imidazo[1,2-a]imidazole (9b). Yield: 0.120 g (68%). Colorless oil (SiO2, 
AcOEt/hexane, 3:7). IR (ﬁlm): ν 3403br, 2969m, 1686m, 1423m, 1320m, 1142m, 
1011m, 806m, 731m, 650m. 1H NMR (CDCl3): δ 4.33–4.28 (m, 1H, HC(2’)); 3.98–
3.94 (m, 1H, H2C); 3.68–3.65 (m, 1H, H2C); 3.46–3.41 (m, 1H, H2C(5’)); 3.29–3.24 
(m, 1H, H2C(5’)); 2.10–2.04 (m, 1H, H2C(3’)); 2.06 (s, 3H, Me); 2.03 (s, 3H, Me); 
1.92–1.84 (m, 2H, H2C(4’)); 1.61–1.54 (m, 1H, H2C(3’)). 13C NMR (CDCl3): δ 137.2 
(C=N); 131.0 (C(imid.)); 115.3 (C(imid.)); 68.1 (C(2’)); 50.6 (C(5’)); 47.3 (CH2); 31.7 
(C(3’)); 26.0 (C(4’)); 11.6 (Me); 8.3 (Me). HR-ESI-MS (MeOH + HCOOH): 
178.13416 (calcd 178.13387 for C10H16N3, [M+1]+). [α]D25 = –31 (c 0.4, CH2Cl2). 
 
 
4.5.3. (5aS)-2-Methyl-3-phenyl-5a,6,7,8-tetrahydro-5H-pyrrolo[1,2-
c]imidazo[1,2-a]imidazole (9c). Yield: 0.188 g  (79%). Colorless oil (SiO2, 
AcOEt/MeOH, 7:3). IR (ﬁlm): ν 3420br, 2929m, 1683s, 1447m, 1390m, 1201m, 
1130m, 765m, 704m. 1H NMR (CDCl3): δ 7.42–7.38 (m, 2H, HC(arom.)); 7.34–7.31 
(m, 2H, HC(arom.)); 7.27–7.23 (m, 1H, HC(arom.)); 4.42–4.36 (m, 1H, HC(2’)); 
4.25–4.20 (m, 1H, H2C); 3.90–3.86 (m, 1H, H2C); 3.59–3.53 (m, 1H, H2C(5’)); 3.38–
3.33 (m, 1H, H2C(5’)); 2.32 (s, 3H, Me); 2.16–2.08 (m, 1H, H2C(3’)); 2.00–1.90 (m, 
2H, H2C(4’)); 1.66–1.58 (m, 1H, H2C(3’)). 13C NMR (CDCl3): δ 158.7 (C=N); 136.2 
(1 C(arom.)); 131.1 (C(imid.)); 128.7 (2 CH(arom.)); 126.6 (2 CH(arom.)); 126.1 (1 
CH(arom.); 121.3 (C(imid.)); 67.7 (C(2’)); 50.6 (C(5’)); 49.0 (CH2); 31.8 (C(3’)); 26.0 
(C(4’)); 14.3 (Me). HR-ESI-MS: 239.14214 (calcd 239.14224 for C15H17N3, [M]+). 
[α]D25  = –229 (c 0.25, CH2Cl2). 
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 4.5.4. N-Phenyl-[(5aS)-3-methyl-5a,6,7,8-tetrahydro-5H-pyrrolo[1,2-
c]imidazo[1,2-a]imidazole]-2-carboxamide (9d). Yield: 0.194 g (69%). Colorless oil 
(SiO2, AcOEt/MeOH, 7:3). IR (ﬁlm): ν 3382br, 2973m, 1663m, 1582m, 1570m, 
1439m, 1417m, 1338m, 1304m, 1205m, 1056m, 1024m, 756m, 660m. 1H NMR 
(CDCl3): δ 8.86 (s, 1H, HN); 7.69–7.65 (m, 2H, HC(arom.)); 7.33–7.28 (m, 2H, 
HC(arom.)); 7.07–7.02 (m, 1H, HC(arom.)); 4.41–4.34 (m, 1H, HC(2’)); 4.09–4.04 
(m, 1H, H2C); 3.81–3.76 (m, 1H, H2C); 3.50–3.44 (m, 1H, H2C(5’)); 3.37–3.32 (m, 
1H, H2C(5’)); 2.50 (s, 3H, Me); 2.17–2.11 (m, 1H, H2C(3’)); 2.00–1.90 (m, 2H, 
H2C(4’)); 1.63–1.55 (m, 1H, H2C(3’)). 13C NMR (CDCl3): δ 162.2 (C=O); 156.4 
(C=N); 138.7 (C(arom.)); 131.8 (C(imid.)); 128.8 (2 CH(arom.)); 127.7 (C(imid.); 
123.2 (1 CH(arom.); 119.5 (2 CH(arom.)); 67.7 (C(2’)); 50.7 (C(5’)); 46.4 (CH2); 31.7 
(C(3’)); 26.0 (C(4’)); 10.1 (Me). HR-ESI-MS (MeOH + HCOOH): 283.15528 (calcd 
283.15534 for C16H19N4O, [M+1]+). [α]D25 = –86 (c 0.375, CH2Cl2). 
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